Older Adults with Type 2 Diabetes (T2D) Experience Less Hypoglycemia when Switching to Insulin Glargine 300 U/mL (Gla-300) vs. Other Basal Insulins (DELIVER 3 Study)

被引：0

|

作者：

Zhou, Fang Liz

Ye, Fen

Gupta, Vineet

Gupta, Rishab

Sung, Jennifer

Berhanu, Paulos

Blonde, Lawrence

机构：

来源：

DIABETES | 2017年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

986-P

引用

收藏

页码：A256 / A256

页数：1

相关论文

共 50 条

[1] Glycaemic control in people with type 2 diabetes (T2D) switching from NPH to insulin glargine 300 U/mL (Gla-300): REALI pooled database
Mueller-Wieland, D.
Freemantle, N.
Bonadonna, R.
Mauquoi, C.
Bigot, G.
Bonnemaire, M.
Gourdy, P.
Mauricio, D.
DIABETOLOGIA, 2022, 65 (SUPPL 1) : S333 - S334
[2] Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching from Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)-DELIVER D
Sullivan, Sean D.
Bailey, Timothy S.
Roussel, Ronan
Zhou, Fang L.
Bosnyak, Zsolt
Preblick, Ron
Westerbacka, Jukka
Gupta, Rishab
Blonde, Lawrence
DIABETES, 2018, 67
[3] The efficacy of switching from Insulin Glargine 100 U/mL (Gla-100) to Insulin Glargine 300 U/mL (Gla-300) in patients with type 2 diabetes mellitus
Yang, K. -H.
Tseng, C. -T.
Chen, L. -C.
Chen, P. -C.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 310 - 310
[4] OLDER PEOPLE WITH T2DM: GLYCEMIC CONTROL AND LESS HYPOGLYCEMIA WITH INSULIN GLARGINE 300 U/ML (GLA-300) VS GLA-100 AT 1 YEAR
Yale, J. F.
Trescoli, C.
Cahn, A.
Lee, M.
Brulle-Wohlhueter, C.
Chevalier, S.
Bolli, G. B.
DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A116 - A116
[5] REAL-WORLD EFFECTIVENESS AND SAFETY OF INSULIN GLARGINE 300 U/ML (GLA-300) IN OLDER ADULTS (≥70 YEARS) WITH TYPE 2 DIABETES (T2D): ATOS STUDY SUBGROUP ANALYSIS
Galstyan, G.
Tirosh, A.
Vargas-Uricoechea, H.
Mabunay, M. A. N.
Coudert, M.
Pilorget, V.
Khan, N.
DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A102 - A102
[6] Cost-Effectiveness of Insulin Glargine 300 units/mL (Gla-300) vs. Insulin Degludec 100 units/mL (IDeg) in T2D
Murphy, Daniel R.
Yu, Xueting
Fournier, Marie
Klein, Timothy M.
Fan, Tao
Perk, Sinem
Preblick, Ronald
Zhou, Fang Liz
DIABETES, 2017, 66 : A354 - A354
[7] Switching to Insulin Glargine 300 U/mL (Gla-300) after Failure of Advanced Insulin Therapy (IT) with Other Basal Insulins (BI) in Patients (Pts) with Type 2 Diabetes (T2DM) Improved Glycemic Control
Pscherer, Stefan
Fritsche, Andreas
Anderten, Helmut
Pegelow, Katrin
Seufert, Jochen
Pfohl, Martin
DIABETES, 2018, 67
[8] Is Hypoglycemia a Modifiable Patient Risk in Type 2 Diabetes? A Pooled Analysis of Insulin Glargine 300U/mL (Gla-300) vs. 100U/mL (Gla-100) Trials
Rosenstock, Julio
Zhang, Quanwu
Gerrits, Charles
Liao, Laura
Chew, Paul
DIABETES, 2015, 64 : A110 - A110
[9] Real-World Health Outcomes of Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Glargine 100 U/mL (Gla-100) in Patients with Type 1 (T1D) and Type 2 Diabetes (T2D) in the Canadian LMC Diabetes Patient Registry-The REALITY Study
Abitbol, Alexander
Brown, Ruth E.
Jiandani, Dishay
Sauriol, Luc
Aronson, Ronnie
DIABETES, 2018, 67
[10] Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching From Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)-DELIVER D plus Subgroup Analyses
Sullivan, Sean D.
Bailey, Timothy S.
Roussel, Ronan
Zhou, Fang L.
Bosnyak, Zsolt
Preblick, Ron
Westerbacka, Jukka
Gupta, Rishab
Blonde, Lawrence
DIABETES, 2018, 67

← 1 2 3 4 5 →